Tier 2 — strong

Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease

Meilan K Han, Tyler A Barreto, Fernando J Martinez, Adam T Comstock, Umadevi S Sajjan
BMJ open respiratory research 2020 7(1):e000392

Bibliography

PubMed
PMID 32071149
PubMed Central
PMC7047491
DOI
10.1136/bmjresp-2018-000392
Funding
Reported funding/support: http://dx.doi.org/10.13039/100008460National Center for Complementary and Integrative HealthAT007357
Competing interests
Reported disclosure: Competing interests: None declared.

Study snapshot

DesignRandomized placebo-controlled dose-escalation safety trial
ModelHuman intervention research
SampleAdults with mild-to-severe COPD; sample size not stated in abstract
InterventionQuercetin 500, 1,000 or 2,000 mg/day versus placebo
Duration1 week
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2020, this source examined safety, interactions and special populations. Design: Randomized placebo-controlled dose-escalation safety trial. Sample/model: Adults with mild-to-severe COPD; sample size not stated in abstract. The exposure or intervention was Quercetin 500, 1,000 or 2,000 mg/day versus placebo. Follow-up or treatment period: 1 week.

No drug-related severe adverse events were reported over the short dosing period.

Small, short safety study. It does not establish long-term tolerability or COPD treatment efficacy.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Side Effects and Safety: A Practical Guide. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • No drug-related severe adverse events were reported over the short dosing period.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 500, 1,000 or 2,000 mg/day versus placebo; 1 week.

What this study can and cannot tell us

  • Small, short safety study. It does not establish long-term tolerability or COPD treatment efficacy.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019
Tier 2
The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects
Satish Kumar Bedada et al. · European journal of clinical pharmacology · 2018

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology